Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) [Trend Analysis] surged reacts as active mover, shares a gain 1.38% to traded at $5.15 and the percentage gap between open changing to regular change was 0.39%. Keryx Biopharmaceuticals, Inc. (KERX) reported that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for Auryxia (ferric citrate) tablets.
The sNDA acceptance by the FDA indicates that the application is sufficiently complete to permit a substantive review. The Prescription Drug User Fee Act (PDUFA) target action date for completion of the FDA’s review is November 6, 2017.Auryxia is currently authorized for use in the U.S. for the control of serum phosphorus levels in patients with end-stage renal disease requiring dialysis.
Keryx, with this sNDA submission, is seeking to expand the indication for Auryxia to include the treatment of iron deficiency anemia (IDA) in patients with non-dialysis dependent chronic kidney disease (NDD-CKD). The firm’s current ratio calculated as 6.20 for the most recent quarter. The firm past twelve months price to sales ratio was 16.95 and price to cash ratio remained 4.85. As far as the returns are concern, the return on equity was recorded as -524.10% and return on investment was -103.90% while its return on asset stayed at -85.80%.
Exxon Mobil Corporation (NYSE:XOM) [Trend Analysis] attempts to attain leading position in street, Shares price changes as it -1.81% to close at $81.03 with the total traded volume of 16.81 Million shares. A former Exxon Mobil Corp. (XOM) property that’s been on the market for more than two years has been sold. New York- and San Francisco-based Spear Street Capital and Houston-based Transwestern Development Co. reported the acquisition of 16.88 acres at 3120 Buffalo Speedway on March 8.
Ronnie Deyo, Rudy Hubbard and Kevin McConnwith Jones Lang LaSalle marketed the property for Irving, Texas-based Exxon Mobil (NYSE: XOM). No further details were immediately accessible.The Greenway Plaza-area property had been the headquarters of Exxon Mobil Upstream Research Co. since the 1950s. It was put on the market in the summer of 2014 as the energy giant was in the process of consolidating its Houston operations into its 385-acre Springwoods Village campus.
The facility features a six-story, 450,000-square-foot, single-tenant office building, a 100,000-square-foot training center, 13 auxiliary buildings and a large parking structure, the Houston Business Journal declared at the time. The firm has institutional ownership of 52.90%, while insider ownership included 0.30%. Its price to sales ratio ended at 1.55. XOM attains analyst recommendation of 3.10 with week’s performance of -2.40%.